Mankind Pharma IPO Subscription Status
Mankind Pharma IPO received bids for 42,95,12,902 shares against 2,80,41,192 offered, an overall subscription of 15.32x at the close of bidding (27 Apr 2023). QIBs lead at 49.16x, while Retail (0.92x) portion is undersubscribed.
Last updated · day 3 figures
- Retail
- 0.92x
- NII
- 3.80x
- QIB
- 49.16x
- Total
- 15.32x
Where the demand is
Mankind Pharma IPO subscription by category
| Category | Shares offered | Shares bid | Amount bid | Subscription |
|---|---|---|---|---|
| QIB | 80,11,769 | 39,38,34,103 | ₹42,534.08 Cr | 49.16x |
| NII | 60,08,827 | 2,28,22,761 | ₹2,464.86 Cr | 3.80x |
| Retail | 1,40,20,596 | 1,28,56,038 | ₹1,388.45 Cr | 0.92x |
| Total | 2,80,41,192 | 42,95,12,902 | ₹46,387.39 Cr | 15.32x |
* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.
Mankind Pharma IPO subscription day-wise
| Category | Day 3 |
|---|---|
| QIB | 49.16x |
| NII | 3.80x |
| Retail | 0.92x |
| Total | 15.32x |
| Total added | 15.32x |
Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.
Mankind Pharma IPO reservation
| Category | Shares | Share of issue |
|---|---|---|
| Qualified Institutional Buyers | 80,11,769 | 28.57% |
| Non-Institutional Investors | 60,08,827 | 21.43% |
| Retail Individual Investors | 1,40,20,596 | 50.00% |
| Public issue | 2,80,41,192 | 100% |
Allotment Chances Note
These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:
- Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
- Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
- Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.
Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.
Mankind Pharma IPO subscription: FAQs
- What is the overall subscription of Mankind Pharma IPO?
- Mankind Pharma IPO is subscribed 15.32x overall as of day 3 (27 April 2023), with bids for 42,95,12,902 shares against 2,80,41,192 offered.
- What is the retail subscription of Mankind Pharma IPO?
- The retail portion is subscribed 0.92x as of day 3 (27 April 2023).
- What is the QIB and NII subscription of Mankind Pharma IPO?
- QIBs have subscribed 49.16x of their portion, and NIIs 3.80x as of day 3 (27 April 2023).
- How can I check Mankind Pharma IPO subscription status live?
- This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
- How do I apply for Mankind Pharma IPO?
- Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 27 April 2023.
Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.